Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the results of its Annual and Special Meeting of Shareholders held today, May 14, 2024 (the “Meeting”).

Satellos is pleased to announce that all of the nominees listed in the management information circular dated April 10, 2024 (the “Circular”), were elected as directors. Each director was elected with greater than 99% of the votes cast by shareholders present at the Meeting or represented by proxy with a total of 54.43% of the issued and outstanding common shares of the Company represented in person and by proxy at the Meeting.

The results of the vote are detailed below:

Director	Votes For	% For	Votes Against	% Against
Frank Gleeson	56,405,629	99.95	29,502	0.05
Rima Al-awar	56,378,453	99.90	56.678	0.10
Franklin M. Berger	56,401,479	99.94	33,652	0.06
Brian Bloom	56,396,279	99.93	38,852	0.07
William (Bill) Jarosz	56,375,448	99.89	59,683	0.11
Geoff Mackay	56,396,348	99.93	38,783	0.07
William (Bill) McVicar	56,401,798	99.94	33,333	0.06